Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the impact of concurrent versus sequential
administration of abiraterone acetate plus prednisone on the ability to manufacture
sipuleucel-T (by assessing sipuleucel-T product parameters), and to assess the safety and
efficacy of sipuleucel-T with concurrent or sequential administration of abiraterone acetate
plus prednisone in men with metastatic castrate resistant prostate cancer.